AG
KYMR icon

Algert Global’s Kymera Therapeutics KYMR Stock Holding History

Algert Global’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$393K Sell
3,430
-1,400
-29% -$120K ﹤0.01% 1107
2026
Q1 		$402K Buy
+4,830
New +$382K 0.01% 989
2025
Q3 		– Sell
-10,850
Closed -$473K – 1248
2025
Q2 		$473K Buy
+10,850
New +$374K 0.01% 946
2024
Q4 		– Sell
-30,256
Closed -$1.43M – 1252
2024
Q3 		$1.43M Sell
30,256
-2,450
-7% -$108K 0.04% 671
2024
Q2 		$976K Buy
32,706
+4,622
+16% +$160K 0.03% 694
2024
Q1 		$1.13M Sell
28,084
-71,288
-72% -$2.55M 0.04% 584
2023
Q4 		$2.53M Sell
99,372
-29,160
-23% -$521K 0.1% 335
2023
Q3 		$1.79M Buy
128,532
+72,802
+131% +$1.46M 0.08% 400
2023
Q2 		$1.28M Buy
+55,730
New +$1.6M 0.06% 566
2022
Q2 		– Sell
-8,242
Closed -$349K – 1303
2022
Q1 		$349K Buy
8,242
+3,591
+77% +$152K 0.02% 931
2021
Q4 		$295K Buy
4,651
+440
+10% +$25.6K 0.04% 734
2021
Q3 		$247K Buy
+4,211
New +$244K 0.03% 829

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Algert Global's KYMR Position: Q2 2026 in Review

Algert Global reduced its Kymera Therapeutics (KYMR) stake by 29% in Q2 2026, selling an estimated $120K and leaving 3,430 shares worth $393K. The position accounts for ﹤0.01% of the portfolio, ranked #1107.

Algert Global first reported a position in KYMR in Q3 2021 and has held it in 12 quarters since. The position peaked at $2.53M in Q4 2023. 275 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • Algert Global held 3,430 shares of Kymera Therapeutics worth $393K as of Q2 2026.
  • Algert Global sold 1,400 Kymera Therapeutics shares in Q2 2026, an estimated $120K.
  • Kymera Therapeutics made up ﹤0.01% of Algert Global's portfolio in Q2 2026, its #1107 holding.
  • Algert Global first reported a position in Kymera Therapeutics in Q3 2021 and has held it in 12 quarters since.
  • Algert Global's Kymera Therapeutics position peaked at $2.53M in Q4 2023.
  • 275 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Algert Global's 13F filing for Q2 2026, filed 13 Aug 2026.